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Discussion: Session 1*
Detection of Health Effects of
Exposure to Low Doses of Agents-
Scientific Constraints
The discussion opened with consideration of the
suitability of animal models for extrapolation to
human disease. Dr. Alarie pointed out that for
some carcinogens, such as vinyl chloride, animal
data had proved to be quite predictive of human
effects. He commented that methods developed by
Dow Chemical Company in studying uptake and
excretion ofseveral chemicals had taken account of
metabolic differences between animals and man,
when the human data were available. He also
believes that by means of kinetic models, for at
least some inhaled chemicals, it will be possible in
the next few years to estimate human effects from
animal data in reasonably quantitative terms. Dr.
Land mentioned that for a physical agent such as
ionizing radiation, animal data were useful for
studying mechanisms of action.
There followed discussion ofthe comparability of
routes of exposure. Dr. Julian Andelman (Univer-
sity of Pittsburgh) asked if inhalation exposure
limits could give guidance to exposure limits for
chemicals in water or food. There was general
agreement by Drs. Esmen and Alarie that for
some materials which are absorbed and metabo-
lized in the same way, regardless ofroute ofentry,
this approach was reasonable, but in general such
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equivalence was not the case. For systemic toxic
effects, the inhalation route could be equated to
ingestion only if comparable blood levels could be
established. Dr. Radford pointed out that gastro-
intestinal absorption involved uptake into the por-
tal circulation, which could be very different from
equivalent uptake from the lungs. Dr. Alarie
agreed that biotransformations in the liver or in
the blood itself may modify effects for certain
rapidly metabolized chemicals such as cyanide, but
forothers there would be relatively little difference.
Dr. Gordon Newell (Assembly of Life Sciences,
National Research Council) asked ifDr. Alarie had
noted marked differences in response by different
species, for example, the carcinogenic response to
formaldehyde. Dr. Alarie agreed that the response
to irritants was highly variable even by strain of
mice. Afterexposure to formaldehyde, nasal tumors
had been found in rats but not in mice, but if the
exposure concentrations were to be increased by a
factor of 2 or 3, the results may not be negative in
mice. He believes that it is too early to draw firm
conclusions from this progressing study on nasal
cancer from formaldehyde.
Dr. Jess Kraus (University of California at
Davis) asked Dr. Alarie the basis ofhis selection of
0.03 times the RD50 as an 8-hr time-weighted
average exposure limit to irritant gases or vapors.
Dr. Alarie replied that it was a practical compro-
mise in order to keep the average below 10% of
the irritant dose. Reduction ofthe value to 3% was
arbitrary. Dr. Marvin Schneiderman further com-
mented that, because the slope of the RD50 values
was not unity, TLVs for highly irritant materials
would be too high and those for less toxic materi-
als would be too low. Dr. Alarie agreed that this
interpretation was correct. In response to a fur-
ther question on this point by Dr. Joseph Meyer
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error in the x-axis ofhis graph and the effects this
could have on the slope, Dr. Alarie agreed that the
difference between the observed slope of 0.83 and
1 was perhaps not significant. He indicated that
the analysis presented was still preliminary and
warranted further statistical and other evaluation.
The discussion then turned to dose-response
relationships. Dr. Philip Enterline pointed out that
the linear, no-threshold dose response was com-
monly used by EPA, and he asked Dr. Altshuler
which type of relationship he preferred among the
models he had discussed. Dr. Altshuler replied
that he gives greatest credibility to multistage
models. He believes that the EPA approach, using
the linear no-threshold dose response, is reason-
able and conservative, and it is consistent with the
multistage model at low doses. Dr. Enterline
continued with the question of extrapolation from
high doses, as has been done frequently; Dr.
Altshuler defended this procedure on practical
grounds because often some decision has to be
reached based on very limited data. The latter is
not really a scientific issue, but is a practical policy
matter.
Dr. Marvin Schneiderman stated that, because
of competing risks, the time-to-occurrence of an
effect with a relatively long latent period may be
quite independent of dose, and he asked Dr.
Altshuler to comment. In reply, Dr. Altshuler said
that, if you believe the multistage model, the
effect of a change of dose is a shift vertically in the
response curve, i.e., perpendicular to the time
axis. This implies at relatively low response levels
that the average time to tumor corrected for
premature death does not change with dose. Thus,
average or median age to an observed effect is
very insensitive to dose and is not a good index of
response. Dr. Radford pointed out that animal
data frequently do show an effect ofdose on cancer
latent period, to which Dr. Altshuler responded
that animal data are generally obtained at high
doses, with large fractions of the animals getting
cancers. When most animals develop cancer, the
multistage model also implies that the average
time is going to decrease. The insensitivity of
latent period to dose occurs only in the situation
where there is low response and numbers at risk
do not change significantly with dose in the course
of the, experiment.
Dr. Radford asked Dr. Land to comment on
interpreting animal data on radiation-induced can-
cer, applying Altshuler's multistage model, which
is quite well accepted. Experimental animals are
not exposed to the many additional environmental
factors that can influence carcinogenesis in man.
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Thus, how would one anticipate that this situation
could modify interpretations of the dose-response
data in animals compared to man? He indicated
that in man, because ofthe numerous other agents
to which people are exposed and which can act as
co-carcinogens or cancer promoters, the induction
step for cancer may be the primary determinant of
a human cancer response, in contrast to the
situation with animals. Dr. Land replied that in
animal studies the responses are usually to very
high exposure levels, whereas in studies of people
we are talking about low levels ofresponse, at the
most, a tripling or quadrupling of a generally low
normal site-specific risk. Animals that are studied
for carcinogenesis often have high natural levels of
cancer, and he considered that maybe the behavior
of the dose response for very high doses does not
have much to do with the dose dependence of risk
at the low end of the scale.
Dr. Andelman asked about the problem of vari-
ability of exposures within a population under
epidemiologic study in defining the relevant dose
parameters. Dr. Esmen stated that the dose
estimation process should not influence the results.
Ifthe population has a particular mode ofexposure
which can be measured, then he said that exposure
of the population through that mode has the
measured distribution, provided that other routes
of exposure are not dominant. But in a case where
the exposures from all modes are extremely varied
and are all about the same order of magnitude, it
is not certain one can really estimate an exposure
with any sort ofreliability. A good example ofthis
latter case would be ifwe try to gauge the effect of
being exposed to airborne particulates in a large
city without being able to measure personal expo-
sures. If exposures at work, at home, or at
hobbies cannot be evaluated, then what one is
saying is that exposure to some components ofthe
mix of inhaled particles cannot be estimated,
perhaps even to within an order of magnitude or
more.
Dr. Andelman cited the issue of lead exposure
among the general population. Much of the evi-
dence indicates the exposures are probably distri-
buted lognormally. One evidence of this is the
distribution of blood levels. In that kind of situa-
tion, what does the epidemiologist do to try to
study the effects of lead on a population? One
should try to find populations that are exposed to
specific concentrations, individual by individual, or
in a particular case, perhaps the whole population.
But this situation is usually not the case. There-
fore, how do you deal with this problem in trying
to interpret effects in response to such variable
doses? Dr. Esmen replied that, if you know the
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can estimate its parameters, you can have a
reasonable answer. The choice of more and more
refined techniques would complicate the mathe-
matics, but it is still possible. The main problem is
what happens if one really cannot define the
distribution of exposures, especially if an unmeas-
ured or unmeasurable one dominates the dose. Dr.
Radford pointed out that the fact that the blood
lead is lognormally distributed in a population does
not necessarily say anything at all about the
distribution of exposures. It is more indicative of
individual metabolism, either absorption in the GI
tract, or excretion by the kidneys or the intestinal
tract, rather than a difference in exposure.
Dr. Andelman also asked about the effect on
dose response of variable susceptibility among the
study population. Dr. Esmen agreed that this was
a further complication added to that of the dose
distribution. Dr. Altshuler indicated that for these
distributional problems one can take the linear
approach according to which the effects are addi-
tive. The median should not be used, as is usually
done with a lognormal distribution. Use of the
average, which is relatively simple to calculate as
a first order ofapproximation, should be sufficiently
precise for epidemiologic studies. Dr. Philip J.
Walsh (Oak Ridge National Laboratory) stated
that if the linear no-threshold hypothesis is used,
and there is a wide distribution of exposures,
those exposed to higher doses have a higher
probability of contracting a disease. Use of aver-
age exposure estimates will therefore overes-
timate risk, because the effective dose will be
underestimated. Dr. Altshuler replied that he
thought that the difficulty in the extrapolation
problem is that, in general, one does not know
enough about the true dose-response relationship
to determine what is happening at high dose and
what is happening at very low dose. He added that
observed data at very low doses for estimation of
low dose effects are needed. One has to continue to
work with biologically plausible theories.
Dr. Radford commented that previous state-
ments suggested that the Druckrey hypothesis did
not apply to low doses. According to this hypothe-
sis, if the dose is low enough, then the latent
period is so long that it is longer than the life-span
of the species, and therefore there is a "true
threshold." According to earlier statements that
argument is not generally valid. Dr. Altshuler
replied that that was a glib dismissal of the real
problem. The distributions of latent periods and
sensitivity all have tails and none of the tails go
out beyond the life ofthe animal species unless you
build into the theory, as an unproven assumption,
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limited susceptibilities and these thresholds extend
indefinitely as dose approaches zero. He believed
there are no data to support this idea.
Dr. Land commented that, for radiation-induced
breast cancer or lung cancers, when you look at
groups exposed to high enough doses, where the
relative risk is greater than two or three, the
distribution of excess cancers over time following
exposure to radiation appears to be the same as
the distribution over time ofcancers not caused by
radiation. This result suggests that, at these dose
levels, there is not any dependence oflatent period
on dose. In the case ofradiation-induced leukemia,
among heavily exposed persons, leukemias tended
to occur earlier than those among lightly exposed
persons, just because more of them were radiation-
caused. The temporal distribution of the naturally
occurring cancers corresponded to the natural
age-specific rates for leukemia. It is possible to
study the latent periods of radiation-induced can-
cers because there are groups under study of
persons who received exposures at a particular
time, such as the Japanese A-bomb survivors. He
indicated that it seemed significant that from these
data there does not seem to be evidence of a
relationship between dose and latent period.
Dr. Schneiderman commented that, if the carci-
nogenic process requires another latent phenome-
non in the multistage process and the latent-stage
phenomenon is age-related and genetically con-
trolled as the final trigger, then one would find
precisely the effect Dr. Land reported in human
populations. That is, the distribution ofthe geneti-
cally triggered age-related phenomenon will occur
at the same age no matter what the initiating
effect was. Animal populations with which we
work are artificial populations. They are kept alive
as populations because we keep them alive. These
are not animals that have responded to particular
evolutionary pressures for survival; in fact, the
evolutionary pressure would be to wipe out the
strain. What is peculiar about these artificial
animal populations is that this genetically driven
age-related, last-stage phenomenon may come very
early in their lives. Thus, the whole process
becomes complicated because we should think of
some genetically driven promotional effect on can-
cer induction. All we have been talking about so
far have been initiating effects, which are not
genetically driven.
Dr. Newell added that what Dr. Schneiderman
way saying could also be thought ofin terms ofthe
fact that animal studies for the most part are
always done with carefully bred and homogeneous
populations as opposed to the people in the room
31who are very heterogeneous. He also raised the
question of whether DNA repair capabilities of
man and of experimental animals are very differ-
ent. For example, for aflatoxins the trout is one of
the most sensitive animals in developing massive
liver tumors at exposure to low levels in a short
time. Incontrast, humangroups exposed to aflatoxin
seem to die of liver toxicity more than from liver
tumors.
Environmental Health Perspectives 32